Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma.

ABSTRACT:

Importance

Immunotherapies are the preferred frontline treatment for most hepatocellular carcinomas (HCCs), but only a small subset of patients attain complete responses to immunotherapies, resulting in an absence of radiographic apparent disease. The clinical importance of these complete responses is unclear, and whether clinical or molecular features may define HCCs that are exquisitely sensitive to immunotherapies is ambiguous.

Objective

To describe the long-term survival outcomes of complete responders to immunotherapies, and to examine whether clinical and genomic characteristics are associated with complete response.

Design, setting, and participants

This cohort study includes a post hoc analysis of the IMbrave150 trial (which enrolled patients across 17 countri

SUBMITTER: Lim M 

PROVIDER: S-EPMC11862977 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature